Review

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Department of Gynecology & Obstetrics, Tianjin Medical University General Hospital, Tianjin, China

Da Yang

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Search for more papers by this author

Yan Sun

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

Search for more papers by this author

Ilya Shmulevich

Institute for Systems Biology, Seattle, WA, USA

Search for more papers by this author

Fengxia Xue

Department of Gynecology & Obstetrics, Tianjin Medical University General Hospital, Tianjin, China

Search for more papers by this author

Anil K Sood

Department of Cancer Biology & Center for RNAi & Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Search for more papers by this author

Wei Zhang

* Author for correspondence

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Search for more papers by this author

Email the corresponding author at wzhang@mdanderson.org

Published Online:12 Oct 2012https://doi.org/10.2217/pgs.12.137

View article

Abstract

A key function of BRCA1 and BRCA2 is the participation in dsDNAbreak repair via homologous recombination. BRCA1 and BRCA2 mutations, which occur in most hereditary ovarian cancers (OCs) and approximately 10% of all OC cases, are associated with defects in homologous recombination and genomic instability, a phenotype termed ‘BRCAness’. The clinical effects of BRCA1 and BRCA2 mutations have commonly been analyzed together; however, it is becoming increasingly apparent that these mutations do not have the same effects in OC. Recently, three major reports highlighted the unequal clinical characteristics of OCs with BRCA1 and BRCA2 mutations. All studies demonstrated that BRCA2-mutated patients are associated with better survival and therapeutic response than BRCA1-mutated and wild-type patients with serous OC. The differing prognostic effects of the BRCA2 and BRCA1 mutations is likely due to differing roles of BRCA1 and BRCA2 in homologous recombination repair and a stronger association between the BRCA2 mutation and a hypermutator phenotype. These new findings have potentially important implications for clinical management of patients with serous OC.

Keywords:

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

1 Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol. Oncol.124(2),347–353 (2012).
Medline CASGoogle Scholar
2 King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science302(5645),643–646 (2003).
Medline CASGoogle Scholar
3 Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol.25(11),1329–1333 (2007).
MedlineGoogle Scholar
4 Sakai W, Swisher EM, Karlan BY et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature451(7182),1116–1120 (2008).
Medline CASGoogle Scholar
5 Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res.68(8),2581–2586 (2008).
Medline CASGoogle Scholar
6 Yang D, Khan S, Sun Y et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA306(14),1557–1565 (2011).▪ A comprehensive analysis of The Cancer Genome Atlas data on different effect of BRCA1 and BRCA2 mutations on drug response and hypermutator phenotype in ovarian cancer.
Medline CASGoogle Scholar
7 Hyman DM, Zhou Q, Iasonos A et al. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer118(15),3703–3709 (2011).▪ Another important report of improved survival of BRCA2-mutated ovarian cancer patients.
MedlineGoogle Scholar
8 Bolton Kl, Chenevix-Trench G, Goh C et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA307(4),382–390 (2012).▪▪ Large multicenter study on differing effect of BRCA1 and BRCA2 mutations on ovarian cancer survival.
Medline CASGoogle Scholar
9 Liu J, Cristea MC, Frankel P et al. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet.205(1–2),34–41 (2012).
Medline CASGoogle Scholar
10 Reitsma W, de Bock GH, Oosterwijk JC, Ten Hoor KA, Hollema H, Mourits MJ. Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different? Int. J. Gynecol. Cancer22(4),579–585 (2012).
MedlineGoogle Scholar
11 Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case–control studies of ovarian cancer. Am. J. Hum. Genet.60(3),496–504 (1997).
Medline CASGoogle Scholar
12 Risch HA, McLaughlin JR, Cole DE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet.68(3),700–710 (2001).
Medline CASGoogle Scholar
13 Rubin SC, Blackwood MA, Bandera C et al.BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am. J. Obstet. Gynecol.178(4),670–677 (1998).
Medline CASGoogle Scholar
14 Pal T, Permuth-Wey J, Betts JA et al.BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer104(12),2807–2816 (2005).
Medline CASGoogle Scholar
15 Press JZ, De Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer8,17 (2008).
MedlineGoogle Scholar
16 Levine DA, Argenta PA, Yee CJ et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J. Clin. Oncol.21(22),4222–4227 (2003).
Medline CASGoogle Scholar
17 Crum CP, Drapkin R, Miron A et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr. Opin Obstet. Gynecol.19(1),3–9 (2007).
MedlineGoogle Scholar
18 Norquist BM, Garcia RL, Allison KH et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer116(22),5261–5271 (2010).
Medline CASGoogle Scholar
19 Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature474(7353),609–615 (2011).
Medline CASGoogle Scholar
20 Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat. Rev. Cancer10(11),803–808 (2010).
Medline CASGoogle Scholar
21 Kuo KT, Mao TL, Jones S et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am. J. Pathol.174(5),1597–1601 (2009).
Medline CASGoogle Scholar
22 Jones S, Wang TL, Shih Ie M et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science330(6001),228–231 (2010).
Medline CASGoogle Scholar
23 Wiegand KC, Shah SP, Al-Agha OM et al.ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med.363(16),1532–1543 (2010).
Medline CASGoogle Scholar
24 Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J. K-RAS mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer79(8),1581–1586 (1997).
Medline CASGoogle Scholar
25 Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum. Pathol.40(9),1213–1223 (2009).
Medline CASGoogle Scholar
26 Piek JM, Torrenga B, Hermsen B et al. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam. Cancer2(2),73–78 (2003).
MedlineGoogle Scholar
27 Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE. Frequency of BRCA1 dysfunction in ovarian cancer. J. Natl Cancer Inst.94(1),61–67 (2002).
Medline CASGoogle Scholar
28 Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, Deyoung B, Buller RE. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J. Natl Cancer Inst.94(18),1396–1406 (2002).
Medline CASGoogle Scholar
29 Lim Sl, Smith P, Syed N et al. Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. Br. J. Cancer98(8),1452–1456 (2008).
Medline CASGoogle Scholar
30 Wang Z, Li M, Lu S, Zhang Y, Wang H. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia–BRCA pathway. Cancer Biol. Ther.5(3),256–260 (2006).
Medline CASGoogle Scholar
31 D’Andrea AD. The Fanconi anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle2(4),290–292 (2003).
MedlineGoogle Scholar
32 Soegaard M, Kjaer SK, Cox M et al.BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin. Cancer Res.14(12),3761–3767 (2008).
Medline CASGoogle Scholar
33 Risch HA, McLaughlin JR, Cole De et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl Cancer Inst.98(23),1694–1706 (2006).
Medline CASGoogle Scholar
34 Shaw PA, McLaughlin JR, Zweemer RP et al. Histopathologic features of genetically determined ovarian cancer. Int. J. Gynecol. Pathol.21(4),407–411 (2002).
Medline CASGoogle Scholar
35 Tan DS, Rothermundt C, Thomas K et al. ‘BRCAness’ syndrome in ovarian cancer: a case–control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin. Oncol.26(34),5530–5536 (2008).
MedlineGoogle Scholar
36 Vencken PM, Kriege M, Hoogwerf D et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann. Oncol.22(6),1346–1352 (2011).
Medline CASGoogle Scholar
37 Gallagher DJ, Konner JA, Bell-McGuinn KM et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann. Oncol.22(5),1127–1132 (2011).
Medline CASGoogle Scholar
38 Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat. Rev. Cancer4(10),814–819 (2004).
Medline CASGoogle Scholar
39 Gourley C, Michie Co, Roxburgh P et al. Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J. Clin. Oncol.28(15),2505–2511 (2010).
MedlineGoogle Scholar
40 Aida H, Takakuwa K, Nagata H et al. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin. Cancer Res.4(1),235–240 (1998).
Medline CASGoogle Scholar
41 Artioli G, Borgato L, Cappetta A et al. Overall survival in BRCA-associated ovarian cancer: case–control study of an Italian series. Eur. J. Gynaecol. Oncol.31(6),658–661 (2010).
Medline CASGoogle Scholar
42 Ben David Y, Chetrit A, Hirsh-Yechezkel G et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J. Clin. Oncol.20(2),463–466 (2002).
Medline CASGoogle Scholar
43 Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA283(17),2260–2265 (2000).
Medline CASGoogle Scholar
44 Buller RE, Shahin MS, Geisler JP, Zogg M, De Young BR, Davis CS. Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin. Cancer Res.8(5),1196–1202 (2002).
Medline CASGoogle Scholar
45 Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer97(9),2187–2195 (2003).
Medline CASGoogle Scholar
46 Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J. Clin .Oncol.26(1),20–25 (2008).
MedlineGoogle Scholar
47 Hennessy BT, Timms KM, Carey MS et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J. Clin. Oncol.28(22),3570–3576 (2010).
MedlineGoogle Scholar
48 Jóhannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J. Clin. Oncol.16(2),397–404 (1998).
Medline CASGoogle Scholar
49 Kringen P, Wang Y, Dumeaux V et al.TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival. BMC Cancer5,134 (2005).
MedlineGoogle Scholar
50 Lacour RA, Westin SN, Meyer LA et al. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol. Oncol.121(2),358–363 (2011).
Medline CASGoogle Scholar
51 Pal T, Permuth-Wey J, Kapoor R, Cantor A, Sutphen R. Improved survival in BRCA2 carriers with ovarian cancer. Fam. Cancer6(1),113–119 (2007).
Medline CASGoogle Scholar
52 Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res.59(4),868–871 (1999).
Medline CASGoogle Scholar
53 Ragupathy K, Ferguson M. Pattern and chemosensitivity of ovarian cancer in patients with BRCA1/2 mutations. J. Obstet. Gynaecol.31(2),178–179 (2011).
Medline CASGoogle Scholar
54 Ramus SJ, Fishman A, Pharoah PD, Yarkoni S, Altaras M, Ponder BA. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur. J. Surg. Oncol.27(3),278–281 (2001).
Medline CASGoogle Scholar
55 Rubin SC, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N. Engl. J. Med.335(19),1413–1416 (1996).
Medline CASGoogle Scholar
56 Zweemer RP, Verheijen RH, Coebergh JW et al. Survival analysis in familial ovarian cancer, a case control study. Eur. J. Obstet. Gynecol. Reprod. Biol.98(2),219–223 (2001).
Medline CASGoogle Scholar
57 Dann RB, Deloia JA, Timms KM et al.BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol. Oncol.125(3),677–682 (2012).
Medline CASGoogle Scholar
58 Mankoo PK, Shen R, Schultz N, Levine DA, Sander C. Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles. PLoS ONE6(11),e24709 (2011).
Medline CASGoogle Scholar
59 Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat. Genet.30(3),285–289 (2002).
MedlineGoogle Scholar
60 Joukov V, Groen AC, Prokhorova T et al. The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell127(3),539–552 (2006).
Medline CASGoogle Scholar
61 Lou Z, Minter-Dykhouse K, Chen J. BRCA1 participates in DNA decatenation. Nat. Struct. Mol. Biol.12(7),589–593 (2005).
Medline CASGoogle Scholar
62 Sankaran S, Crone DE, Palazzo RE, Parvin JD. BRCA1 regulates gamma-tubulin binding to centrosomes. Cancer Biol. Ther.6(12),1853–1857 (2007).
Medline CASGoogle Scholar
63 Starita LM, Machida Y, Sankaran S et al. BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol. Cell. Biol.24(19),8457–8466 (2004).
Medline CASGoogle Scholar
64 Drost R, Bouwman P, Rottenberg S et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell.20(6),797–809 (2011).▪ Important study on different domain mutations of BRCA1 inducing different effects on tumor suppression and therapy resistance.
Medline CASGoogle Scholar
65 Narod SA, Neuhausen S, Vichodez G et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br. J. Cancer99(2),371–374 (2008).
Medline CASGoogle Scholar
66 Ferrone CR, Levine DA, Tang LH et al.BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J. Clin. Oncol.27(3),433–438 (2009).
Medline CASGoogle Scholar
67 Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J. Clin. Oncol.22(4),735–742 (2004).
Medline CASGoogle Scholar
68 Hahn SA, Greenhalf B, Ellis I et al.BRCA2 germline mutations in familial pancreatic carcinoma. J. Natl Cancer Inst.95(3),214–221 (2003).
Medline CASGoogle Scholar
69 Moller P, Evans DG, Reis MM et al. Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int. J. Cancer121(5),1017–1020 (2007).
Medline CASGoogle Scholar
70 Lee EH, Park SK, Park B et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res. Treat.122(1),11–25 (2010).
Medline CASGoogle Scholar
71 Foulkes WD, Metcalfe K, Sun P et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin. Cancer Res.10(6),2029–2034 (2004).
Medline CASGoogle Scholar
72 Satagopan JM, Boyd J, Kauff ND et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin. Cancer Res.8(12),3776–3781 (2002).
Medline CASGoogle Scholar
73 Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet.72(5),1117–1130 (2003).
Medline CASGoogle Scholar
74 Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br. J. Cancer83(10),1301–1308 (2000).
MedlineGoogle Scholar
75 Hall JM, Lee Mk, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science250(4988),1684–1689 (1990).
Google Scholar
76 Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science266(5182),66–71 (1994).
Medline CASGoogle Scholar
77 Sy SM, Huen MS, Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc. Natl Acad. Sci. USA106(17),7155–7160 (2009).
Medline CASGoogle Scholar
78 Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature378(6559),789–792 (1995).
Medline CASGoogle Scholar
79 Esashi F, Christ N, Gannon J et al. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature434(7033),598–604 (2005).
Medline CASGoogle Scholar
80 Ayoub N, Rajendra E, Su X, Jeyasekharan AD, Mahen R, Venkitaraman AR. The carboxyl terminus of BRCA2 links the disassembly of Rad51 complexes to mitotic entry. Curr. Biol.19(13),1075–1085 (2009).
Medline CASGoogle Scholar
81 Davies OR, Pellegrini L. Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats. Nat. Struct. Mol. Biol.14(6),475–483 (2007).
MedlineGoogle Scholar
82 Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer12(1),68–78 (2011).▪▪ Comprehensive and well-written review highlighting the different roles of BRCA1 and BRCA2 in homologous recombination.
MedlineGoogle Scholar
83 Lou Z, Chini CC, Minter-Dykhouse K, Chen J. Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control. J. Biol. Chem.278(16),13599–13602 (2003).
Medline CASGoogle Scholar
84 Hashizume R, Fukuda M, Maeda I et al. The RING heterodimer BRCA1–BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem.276(18),14537–14540 (2001).
Medline CASGoogle Scholar
85 Jensen RB, Carreira A, Kowalczykowski SC. Purified human BRCA2 stimulates RAD51-mediated recombination. Nature467(7316),678–683 (2010).
Medline CASGoogle Scholar
86 Holloman WK. Unraveling the mechanism of BRCA2 in homologous recombination. Nat. Struct. Mol. Biol.18(7),748–754 (2011).
Medline CASGoogle Scholar
87 Baumann P, Benson FE, West SC. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell87(4),757–766 (1996).
Medline CASGoogle Scholar
88 Osher DJ, Kushner YB, Arseneau J, Foulkes WD. Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks? J. Clin. Pathol.64(10),924–926 (2011).
Medline CASGoogle Scholar
89 Evers B, Schut E, van der Burg E et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin. Cancer Res.16(1),99–108 (2009).
MedlineGoogle Scholar
90 Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature434(7035),917–921 (2005).
Medline CASGoogle Scholar
91 Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature434(7035),913–917 (2005).
Medline CASGoogle Scholar
92 Chen A. PARP inhibitors: its role in treatment of cancer. Chin. J. Cancer30(7),463–471 (2011).
MedlineGoogle Scholar
93 Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med.361(2),123–134 (2009).
Medline CASGoogle Scholar
94 Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet376(9737),245–251 (2010).
Medline CASGoogle Scholar
95 Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol.28(15),2512–2519 (2010).
Medline CASGoogle Scholar
96 Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a Phase 2, multicentre, open-label, non-randomised study. Lancet Oncol.12(9),852–861 (2011).
Medline CASGoogle Scholar
97 Kaye SB, Lubinski J, Matulonis U et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol.30(4),372–379 (2012).
Medline CASGoogle Scholar
98 Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med.366(15),1382–1392 (2012).
Medline CASGoogle Scholar
99 Turner NC Lord CJ, Iorns E et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J.27(9),1368–1377 (2008).
Medline CASGoogle Scholar
100 Issaeva N, Thomas HD, Djureinovic T et al. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res.70(15),6268–6276 (2010).
Medline CASGoogle Scholar
101 Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res.67(15),7395–7405 (2007).
Medline CASGoogle Scholar
102 Deans AJ, Khanna KK, Mcnees CJ, Mercurio C, Heierhorst J, Mcarthur GA. Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res.66(16),8219–8226 (2006).
Medline CASGoogle Scholar
103 Dungey FA, Caldecott KW, Chalmers AJ. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol. Cancer Ther.8(8),2243–2254 (2009).
Medline CASGoogle Scholar
104 Chiang JW, Karlan BY, Cass L, Baldwin RL. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol. Oncol.101(3),403–410 (2006).
Medline CASGoogle Scholar
105 Liu GY, Zhang W. Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status? Chin. J. Cancer31(1),1–4 (2012).
MedlineGoogle Scholar

Vol. 13, No. 13

Metrics

Downloaded 414 times

History

Published online 12 October 2012

Published in print October 2012

Information

Keywords

Acknowledgements

The authors would like to thank A Sutton in the Department of Scientific Publications (The University of Texas MD Anderson Cancer Center, TX, USA) for editing this manuscript.

Financial & competing interests disclosure

This study was supported by a grant from the NIH (U24CA143835) to I Shmulevich and W Zhang, a grant from the Blanton-Davis Ovarian Cancer Research Program to W Zhang, an Ovarian Cancer SPORE grant (P50 CA083639) to AK Sood and a grant supported by National Natural Science Foundation of China (grant no. 81101673) to G Liu. D Yang is an Odyssey Fellow at MD Anderson Cancer Center, and supported by The Diane Denson Tobola Fellowship in Ovarian Cancer Research fellowship and The Harold C and Mary L Daily Endowment Fund. Y Sun is supported by The Linda K Manning Fellowship in Ovarian Cancer and The A Lavoy Moore Endowment Fund. G Liu is a New Century outstanding fellow at Tianjin Medical University General Hospital. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer

Abstract

References